TOOsonix and Professor Joergen Serup from University Hospital Bispebjerg Copenhagen were invited to share the plans for a coming clinical study to remove/reduce cutaneous neurofibromas in patients with Neurofibromatosis Type 1. The venue was the annual meeting in the Danish Neurofibromatosis patient association, with participation of a very active and motivated group from all over the country.
The presentation gave the details on the coming dual-center GCP study at Bispebjerg Hospital in Copenhagen Denmark and Sahlgrenska Hospital in Gothenburg Sweden. The study is aimed at using the TOOsonix System ONE-M in a non-ablative modality, where open wounds are avoided, and the regular complications of pain, infection and scarring is drastically reduced.
The study aims at demonstrating a completely new therapeutic solution for patients suffering from Neurofibromatosis Type 1, the most common single-gene inherited condition worldwide (approximately 1 in 3000 people).
Visit the Danish NF accociation here
